You are here: Home Reviews alli (orlistat)


alli (orlistat)


Orlistat is an anti-obesity drug that works by inhibiting the triglycerides uptake from the intestines.


Orlistat 60 mg 3 times a day combined with hypocaloric diet in persons with BMI ≥ 28-43 produced an absolute weight loss of 2,2 kg after 6 months of treatment. After 1 year of treatment the participants sustained a weight loss of 3 – 3,6 kg.


In the studies leading to approval of orlistat 60 mg 50 % of the participants achieved a weight loss of ≥ 5 % of the baseline body weight. Evidence has demonstrated that this level of weight loss is beneficial to parameters of the common co-morbidities of obesity, such as hypertension, diabetes and hypercholesterolemia. 


Generally there is a significantly higher weight loss with orlistat 120 mg x 3 than with 60 mg x 3.


Orlistat does not induce a clinical relevant weight loss in patients with BMI below 28 kg/m2.


10 – 20 % will experience fatty oily stool, faecal urgency and increased defecation.


The price for 6 months of treatment is 2.340 Dkr., corresponding to 13 Dkr. a day.


In comparison the double dose, which is on prescription and leads to a significant higher weight loss, costs 3.600 Dkr. for 6 months of treatment,or 20 Dkr. a day.


IRF states, that the effect of orlistat is minor, and is only recommended with precautions in very obese persons and should always be combined with non-pharmacological treatment as diet and exercise. 


alli is not under the rules of general reimbursement


alli was marketed the 4th of May 2009.

To the topTo the top

Page last updated: 13 May 2009 Print Printspacer Tip a friend Tip a friend spacerTo the top To the top